The chief scientific officer at Quanterix gave a clinical overview on how the company’s Simoa platform enables ultrasensitive detection of neurodegeneration biomarkers in blood, transforming Alzheimer and Parkinson disease research. [WATCH TIME: 3 minutes]
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Elizabeth Head, PhD. [LISTEN TIME: 20 minutes]
The neuroradiologist at Mayo Clinic discussed the clinical and conceptual differences between Alzheimer disease diagnostic frameworks and how clinicians should prepare for a shifting treatment landscape. [WATCH TIME: 4 minutes]
Sonya Miller, medical director at TauRx, discussed the latest clinical data and development plans for HMTM, a potential oral therapy targeting tau pathology in Alzheimer disease.
Philip Kremer, MD, Research Director Neurology, Center for Human Drug Research, provided clinical insights on the early-stage progress of ARV-102, an LRRK2 degrader, in LRRK2-associated diseases.
The professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, gave clinical insights on efforts to refine neuropsychological outcome measures for individuals with Down syndrome at risk for Alzheimer disease. [WATCH TIME: 3 minutes]
The chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]
The vice president of research at Cognition Therapeutics provided commentary on the safety of investigational CT1812 and its role in immune response and synapse-related pathways. [WATCH TIME: 3 minutes]
Elizabeth Head, PhD, a professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, shed light on the emerging research and trials surrounding the interplay between Alzheimer disease and Down syndrome.
ARV-102 showed dose-dependent LRRK2 degradation and favorable safety in its first-in-human trial, supporting its promise for treating LRRK2-linked neurodegenerative diseases.
Neurology News Network. for the week ending April 12, 2025. [WATCH TIME: 3 minutes]
Emer MacSweeney, MD, a consultant neuroradiologist and trial investigator of the phase 3 APOLLOE4 study, provided a clinical view of the latest study findings, and the difficulties with finding treatments for APOEε4/4 carriers of Alzheimer disease.
The neuroradiologist at Mayo Clinic provided clinical insights on the controversy with two recently published Alzheimer criteria, with one diagnosing the disease based on biomarkers alone vs clinical symptoms. [WATCH TIME: 4 minutes]
Murali Doraiswamy, MD, MBBS, a professor of psychiatry and geriatrics at Duke University School of Medicine, gave clinical follow-up on a pivotal analysis of the phase 3 APOLLOE4 study testing a novel therapeutic for Alzheimer disease.
Inge Verberk, PhD, a research associate at the Amsterdam University Medical Center, sat down at AD/PD 2025 to discuss changes in Alzheimer trials, the emergence of plasma biomarkers, and deciphering which biomarkers are of utmost importance.
A recent large-scale analysis presented at the 2025 AD/PD Conference highlighted the role of coping strategies in mitigating negative outcomes.
Neurology News Network. for the week ending April 5, 2025. [WATCH TIME: 3 minutes]
Data suggests that immune dysfunction biomarkers do not pose a major barrier to patient enrollment in Alzheimer’s research, as most patients meeting general AD criteria also qualified under immune dysfunction criteria.
A recent poster presentation at the 2025 AD/PD conference revealed that a novel assay could provide absolute allelic discrimination for APOE genotyping, supporting precision medicine in AD treatment.
An analysis of the Gothenburg Mild Cognitive Impairment Study presented at the 2025 AD/PD Conference reported that lifestyle and socioeconomic factors could significantly influence the risk of developing cognitive diseases.
A new survey study will assess how well German memory clinics and specialists are equipped to provide early and accurate Alzheimer diagnoses using biomarker-based methods.
The Spectris device demonstrated preserved corpus callosum structure and correlated sensory-evoked gamma oscillations in patients with Alzheimer disease, highlighting its potential neuroprotective effects.
Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.
The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.
A pilot study, presented at the 2025 AD/PD conference, evaluating the CUE1 device suggests it may help improve motor symptoms and reduce fall risk in patients with Parkinson disease.
The professor of neurology at Brigham and Women’s Hospital provided clinical insights on her presentation at AD/PD 2025 focusing on the emerging research surrounding complement activation and its influence on amyloid-related imaging abnormalities. [WATCH TIME: 7 minutes]
Recently presented at the 2025 AD/PD Conference, the REAL AD study aims to assess the feasibility of blood biomarkers and digital cognitive testing for early detection of Alzheimer disease.
Investigators at AD/PD 2025 presented new data showing that changes in plasma p-tau217 and p-tau181 closely correlate with clinical outcomes in anti-amyloid therapy trials for Alzheimer disease.
The director of the Alzheimer’s Disease Care, Research, and Education Program at the University of Rochester provided clinical insight on a pivotal trial testing a novel therapeutic in patients with Alzheimer disease who are carriers of APOE4/4. [WATCH TIME: 7 minutes]
